Enigmatic ImClone Rarely has a company reeling from corporate malfeasance been on the receiving end of so much good news. […]

IPO market abuzz with biotech offerings The buzz is biotech — at least as far as initial public offerings are

IPO Market Abuzz with Biotech Offerings “We can expect to see the first IPO take flight in mid-October and we

GE’s Genomic Future On its face, General Electric’s $9.5 billion stock purchase of Amersham is about imaging systems. But the

GE’s Genomic Future On its face, General Electric’s $9.5 billion stock purchase of Amersham is about imaging systems. But the

Financial Snapshot For September 2003 A Temporary Pause

Medicine’s Big Bottleneck If health care companies and the U.S. government do not tread carefully, concerns about the cost of

Medicine’s Big Bottleneck If health care companies and the U.S. government do not tread carefully, concerns about the cost of

Stem cell bill eyed as lure to biotech firms A redraft may be in its future, but supporters of a

What’s Really Banging Up Biovail? The Canadian drugmaker says a truck accident caused it to lower guidance. Wall Street skeptics